Catalog No.S7931

For research use only.

STF-31 is a selective glucose transporter GLUT1 inhibitor.

STF-31 Chemical Structure

CAS No. 724741-75-7

Selleck's STF-31 has been cited by 11 Publications

1 Customer Review

Purity & Quality Control

Choose Selective GLUT Inhibitors

Biological Activity

Description STF-31 is a selective glucose transporter GLUT1 inhibitor.
GLUT1 [1]
In vitro

STF-31 selectively kills RCCs by specifically targeting glucose uptake through GLUT1. STF-31 significantly inhibits lactate production and extracellular acidification in VHL-deficient cells by about 60%, and decreases glycolysis by decreasing glucose transport. [1] In NAPRT1-expressing cells, STF-31 shows cytotoxicity by inhibiting the enzymatic activity of NAMPT. [2] STF-31 is toxic to hPSCs and efficient for selective elimination of hPSCs from mixed cultures. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A2780 cells MmO5SpVv[3Srb36gZZN{[Xl? NEj4NG41QCCq NX2zNY56UW6qaXLpeIlwdiCxZjDORW1RXCCrbjDoeY1idiCDMke4NEBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iTlHEJIxmfmWuIHHmeIVzKDR6IHjyd{BjgSCOQz3NV{9OWyCjbnHsfZNqeyxiSVO1NF0xNjB{NDFOwG0> MVWyOFQ{Ozh3OR?=
RCC4 cells MVvDfZRwfG:6aXPpeJkh[XO|YYm= MmG1OEBl[Xm| NHPOXoVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTS0N2IHPlcIx{KGGodHXyJFQh\GG7czDifUBZXFRiYYPzZZktKEmFNUC9NE4yPiEQvF2= MlfFNlQ{QDd6Nk[=
HT1080 cells M1;Q[3Bzd2yrZnXyZZRqd25iYYPzZZk> MknOPVYhcA>? NWrJS4N3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFExQDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGN6WXWjboStZoF{\WRiYYPzZZktKEmFNUC9NE4zOTNizszN NUfrVI1sOjR2M{O4OVk>
PC3 cells MYHQdo9tcW[ncnH0bY9vKGG|c3H5 NFjoeIc6PiCq M2rGfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCFeWH1ZY51NWKjc3XkJIF{e2G7LDDJR|UxRTBwMkG3JO69VQ>? MnXFNlQ1OzN6NUm=
HCT116 cells MYLQdo9tcW[ncnH0bY9vKGG|c3H5 MV25OkBp NUHOfWg5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGN6WXWjboStZoF{\WRiYYPzZZktKEmFNUC9NE4zPzFizszN MorkNlQ1OzN6NUm=
MIAPaCa2 cells NITieHdRem:uaX\ldoF1cW:wIHHzd4F6 MoL1PVYhcA>? M4CzZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBVIFE[TJiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JGN6WXWjboStZoF{\WRiYYPzZZktKEmFNUC9NE45PTVizszN MnnjNlQ1OzN6NUm=
Methods Test Index PMID
Western blot p-EGFR / HIF-1α / c-Myc / Glut-1 ; TFCP2 / ASIC2a 30967777 28725010
Immunofluorescence ASIC2a / TFCP2 28725010
In vivo In mice with VHL-deficient RCC xenografts, a more soluble analog of STF-31 (11.6 mg/kg, i.p.) markedly delays tumor growth. [1]

Protocol (from reference)

Cell Research:


  • Cell lines: RCC4/VHL and RCC4 cells
  • Concentrations: --
  • Incubation Time: 4 d
  • Method:

    For XTT assays, five thousand cells are plated in 96-well plates. The next day, vehicle (DMSO) or drug is added by serial dilution. Four days later, media are aspirated, XTT solution (0.3 mg/ml of XTT, 2.65 μg/ml N-methyl dibenxopyrazine methyl sulfate in phenol red-free media) is added, and the plates are incubated at 37°C for 1-2 hours. Metabolism of XTT is quantified by measuring the absorbance at 450 nm. IC50s are calculated using linear interpolation. All conditions are measured in triplicate and each experiment is done in duplicate or triplicate.

Animal Research:


  • Animal Models: Mice with VHL-deficient RCC xenografts
  • Dosages: 11.6 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 423.53


CAS No. 724741-75-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NCC2=CC=C(C=C2)C(=O)NC3=CN=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy STF-31 | STF-31 supplier | purchase STF-31 | STF-31 cost | STF-31 manufacturer | order STF-31 | STF-31 distributor